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Results: On macroscopic examination 47 knees had normal, 36 abnormal
and 12 ruptured ACLs. ACL histological scores for collagen degeneration
and the number of blood vessels increased with aging. We compared
with summed cartilage scores to determine the relationship between ACL
and cartilage degeneration. There was a positive correlation between ACL
scores and total, trochlear and medial but not with lateral cartilage scores.
Increased MMP-3 and CD45 expression in ACLs correlated with ACL de-
generation score especially in the gaps between fascicles and in the cell
inﬁltrates around blood vessels.
Conclusions: ACL degeneration correlates with cartilage degeneration,
especially in the medial compartment of the knee joint. This suggests
that ACL deﬁciencies contribute not only to posttraumatic OA but also to
aging-related development of cartilage degradation and OA pathogenesis.
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Purpose: To test the hypothesis that in vivo transgene expression mediated
by adeno-associated virus serotype 2 (AAV2) following single intra-articular
injection of AAV is: (1) localized to the injected joint, (2) persists through
one year after injection, and (3) can be externally controlled.
Methods: Nine male Sprague-Dawley (SD) rats received AAV2-CMV-GFP
and AAV2-CMV-Luciferase (Luc) into their right and left knees, respectively.
Luciferase expression was evaluated over a 1-year period using the IVIS®
Imaging System (Xenogen). After sacriﬁce, tissues within the joint were
analyzed by ﬂuorescence stereomicroscopy to detect GFP+ cells. To study
the ability to control AAV transgene expression in the rat knee joint, an
additional ﬁve male SD rats received AAV2-tetracycline response element
(TRE)-Luc and AAV2-CMV-transcriptional transactivator into the right knee,
and AAV2-CMV-Luc into the left knee. To induce expression of luciferase, 2
mg/ml doxycycline (Dox) was added to the drinking water, and rats were
imaged twice a week as described above.
Results: Luciferase expression was detectable in all rats post-injection.
Long-term rats showed continued and stable luciferase expression through
1 year. GFP+ cells were mainly found in the intra-articular soft tissues
surrounding the articular cartilage, with rare GFP+ chondrocytes. For the
joints injected with inducible AAV-TRE-Luc, gene expression was upregu-
lated (p<0.05) after addition of Dox, and downregulated (p<0.05) following
removal of Dox.
Conclusions: Longitudinal in vivo results show persistent and stable
AAV-mediated gene expression through one year following a single intra-
articular injection. The use of inducible TRE promoter allows the feasibility
to control in vivo transgene expression in the rat knee joint. These results
suggest that AAV is a potential therapeutic approach to deliver growth
factors in the knee joint persistently in a time-controlled manner. The
rare occurrence of GFP+ cells in intact articular cartilage indicates that
more studies on AAV delivery to damaged articular cartilage, which can
progress to osteoarthritis, are needed. This continued characterization of
the length, location and ability to control transgene expression following
intra-articular injection of AAV will help to better tailor gene therapy
for articular cartilage repair, which may delay or prevent the onset of
osteoarthritis.
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Purpose: Tendon lesion is one of the most frequent pathology in sports and
by physical workers. This pathology often becomes chronic. For this reason,
it is of interest to develop new treatments. Injection of platelet-rich plasma
(PRP) seems to be a promising one by releasing growth factors (GF) locally.
Among all the GF released by activated platelets, the vascular endothelial
growth factor-A (VEGF-A) is known to induce positive effects on vascular
function and angiogenesis, and could be implicated in the healing process
of tendons. Recently, a novel VEGF-A isoform was identiﬁed, the VEGF-111,
a biologically active and proteolysis-resistant VEGF-A isoform, also known
to present beneﬁcial effects on ischemic diseases. This prompted us to
evaluate whether VEFF-111 would have a therapeutic interest within the
framework of the tendon pathology.
Methods: 60 Rats were divided into 2 groups: A: control (no injection), B:
VEGF-111 treatment. A 5mm defect was surgically induced in rat Achilles
tendon after resection of plantaris tendon. Rats received a local injection of
VEGF-111 (100ng) in situ after the surgery and were placed in their cages
without immobilization. After 5, 15 and 30 days, the traumatized Achilles
tendons of 10 rats of both groups were removed and dissected during their
healing process. Immediately after sampling, tendons were submitted to
a biomechanical tensile test up to rupture, using a “Cryo-jaw”. Rats were
then euthanized.
Statistical analyses were made with an ANOVA. Values are signiﬁcant when
p-value is below 0.05.
Results: Our results shown that the developed force necessary to induce
tendon rupture during biomechanical tensile test was greater for tendons
which had received an injection of 100ng of VEGF-111. These results were
already noticed from day 5 onwards. The ratio between force and weight
increased with time in both groups, but this ratio was greater for tendons
which had been submitted to an injection of VEGF111. The surface area of
the section of the tendons increased between 5 and 15 days followed by
a stabilization. After 30 days, sections in both groups were similar. Thus,
the constraint was similar after 5 and 15 days but was better for VEGF111
group after one month.
Conclusions: This experimentation has shown that a 100ng injection of
VEGF-111 stimulated tendon healing process as suggested by the increased
force needed to break tendons during its healing process and the increased
of constraint in comparison with the control group. Other experimentations
with different concentration of VEGF111 are now in process.
Acknowledgement: This experimentation was partially ﬁnanced by “Stan-
dard de Liège 2007” and “Lejeune-Lechien 2008” grants.
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Introduction: Meniscal degeneration is a signiﬁcant prognostic factor in
progressive cartilage loss in symptomatic knee osteoarthritis (OA). Despite
this, relatively little is known about the mechanisms of meniscal degener-
ation and whether this differs from articular cartilage (AC). The meniscus
has distinct zones, the inner ∼1/3rd being avascular and ﬁbrocartilaginous
while the outer region is vascular and more ﬁbrous. Recent studies have
examined meniscal degeneration in vitro using explant cultures but have
not directly compared the inner versus outer zones and with AC.
Methods: Ovine AC and inner and outer zone meniscal explants were
dissected from the same joints, and cultured separately for 4 days in
serum free media ± IL-1α (10ng/ml) or TNFα (100ng/ml); n≥6 for all treat-
ments. Matrix metabolism and enzyme activity were assessed by sulphated
glycosaminoglycan (GAG) and collagen (hydroxyproline) release, qRT-PCR
(aggrecan; collagen I & II; MMP-1, -2, -3, -9, -13, & -14; TIMP-1 & -3),
aggrecan neoepitope Western blotting, gelatin zymography, and MMP-13
substrate assay. Only differences where p < 0.05 are reported.
Results: Both meniscal zones had higher GAG release (% total) than AC
in control and cytokine treated cultures. Inner meniscus was similar to
AC with a signiﬁcant increase in GAG release after both cytokines; outer
meniscus showed less response and only to IL-1α. The outer meniscus
was unique in releasing signiﬁcant collagen following cytokine stimu-
lation. Aggrecan loss in control meniscal cultures was associated with
ADAMTS-cleavage (increased NITEGE compared to ex-vivo). IL-1α- and
TNFα-stimulated aggrecan loss in AC and inner meniscus was associated
with increased NITEGE, while cleavage by MMPs (increased DIPEN) pre-
dominated in outer meniscus. Expression of aggrecan, collagen I & II
ex-vivo reﬂected tissue compositions. Aggrecan and collagen mRNA were
decreased in all tissues by IL-1α and TNFα. ADAMTS-5 mRNA was increased
compared with ex-vivo in control meniscal but not AC cultures. IL-1α and
TNFα increased ADAMTS-4 & ADAMTS-5 expression in the meniscus more
than AC, with ADAMTS-4 more responsive to IL-1α and ADAMTS-5 to TNF.
MMP-1, -3, -9, -13 & -14 expression increased in both meniscal zones with
IL-1α and TNFα, while MMP-2 only increased in the outer zone. In contrast,
only MMP-1 and -3 were signiﬁcantly increased by cytokines in AC, and
